Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Screeners

Top Momentum Stocks

Top Quality Stocks

Top Value Stocks

Top Growth Stocks

Comments

Loading...

Innate Pharma Stock News

IPHYFOTCPK

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$1.45

Last update: Dec 31, 7:00 PM

Innate Pharma (IPHYF) Forecast

News

Earnings Innate Pharma (IPHYF) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest Innate Pharma Stock News | OTC:IPHYF | Benzinga

Get the latest news on Innate Pharma stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Innate Pharma performance

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Tuesday, July 06, 2021

Innate Pharma To Stop COVID-19 Trial With Avdoralimab After Mid-Stage Study Disappoints
Vandana Singh - Jul 6, 2021, 7:16AM

Tuesday, June 22, 2021

Innate Pharma's Lacutamab Shows Clinical Responses In KIR3DL2-Expressing Mycosis Fungoides Patients
Vandana Singh - Jun 22, 2021, 9:32AM
Innate Pharma Highlights Presentation Of Preliminary Data from TELLOMAK Trial
Bill Haddad - Jun 22, 2021, 7:01AM

Wednesday, June 09, 2021

Innate Pharma To Present Data From Tellomak Trial At 16th International Conference on Malignant Lymphoma Jun. 22
Bill Haddad - Jun 9, 2021, 6:13AM

Tuesday, February 09, 2021

Innate Pharma To Test Lacutamab In Relapsed/Refractory Peripheral T-Cell Lymphoma Patients
Vandana Singh - Feb 9, 2021, 7:19AM

Monday, January 13, 2020

French Regulatory Agency Agrees lacutamab TEL...
Benzinga Newsdesk - Jan 13, 2020, 5:01PM

Monday, October 07, 2019

Innate Pharma Announces 10.6M ADS IPO @Price to be Determined Following Bookbuilding Process
Charles Gross - Oct 7, 2019, 3:41AM

Thursday, September 26, 2019

Innate Pharma Announces AstraZeneca to Advance Monalizumab to Phase III in Head and Neck Cancer
Charles Gross - Sep 26, 2019, 3:51AM

Monday, January 11, 2016

Sanofi, Innate Pharma Collaborate on New Bispecific NK Cell Engagers in Immuno-Oncology
Benzinga - Jan 11, 2016, 5:25AM

Sunday, January 10, 2016

Innate Pharma in-licenses OREGA biotech's first-in-class anti-CD39 checkpoint inhibitor program
Benzinga - Jan 10, 2016, 6:36PM

Thursday, December 03, 2015

Innate Pharma Announces First patient dosed in Phase I trial of IPH4102
Benzinga - Dec 3, 2015, 4:19AM

Wednesday, June 03, 2015

Astrazeneca, Innate Pharma Announce Global Co-Development and Commercialisation Collaboration for IPH2201 in Immuno-Oncology
Benzinga - Jun 3, 2015, 5:32AM

Friday, April 24, 2015

Innate Pharma and AstraZeneca announce global agreement for IPH2201 in immuno-oncology
Benzinga - Apr 24, 2015, 4:23AM

Thursday, April 16, 2015

Innate Pharma, Sanofi Announce Collaboration on Development of new Antibody Drug Conjugates
Benzinga - Apr 16, 2015, 4:47AM

Monday, March 09, 2015

Innate Pharma Announces Investigators from NCIC CTG Presented Rationale, Protocol of IPH2201 Phase I/II Trial at TAT
Benzinga - Mar 9, 2015, 4:45AM

Friday, December 19, 2014

Innate Pharma Announces First Phase II Trial with IPH2201 Open in Head and Neck Cancer
Benzinga - Dec 19, 2014, 5:13AM

Monday, March 31, 2014

Innate Pharma Announces Bristol-Myers Squibb Conducting Phase I Trial with Lirilumab and Nivolumab in Selected Solid Tumors
Benzinga - Mar 31, 2014, 5:40AM

Wednesday, November 20, 2013

Innate Pharma Raises €20.3M in Private Placement
Benzinga - Nov 20, 2013, 5:51AM

Friday, November 15, 2013

Innate Pharma Initiates Iph43 Program to Develop First-In-Class Anti-Mica Antibody
Benzinga - Nov 15, 2013, 6:04AM

Connect With Us

About Benzinga

About Us
Careers
Advertise
Contact Us

Market Resources

Advanced Stock Screener Tools
Options Trading Chain Analysis
Comprehensive Earnings Calendar
Dividend Investor Calendar and Alerts
Economic Calendar and Market Events
IPO Calendar and New Listings
Market Outlook and Analysis
Wall Street Analyst Ratings and Targets

Trading Tools & Education

Benzinga Pro Trading Platform
Options Trading Strategies and News
Stock Market Trading Ideas and Analysis
Technical Analysis Charts and Indicators
Fundamental Analysis and Valuation
Day Trading Guides and Strategies
Live Investors Events
Pre market Stock Analysis and News
Cryptocurrency Market Analysis and News

Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved